Annexin A10 (ANXA10)

Annexin A10 is the most recently identified member of the annexin family, which are highly conserved phospholipid-binding proteins with variable involvement in membrane–cytoskeleton interaction, calcium-dependent signaling, and nuclear functions. Unlike most annexins, ANXA10 displays atypical biochemical features—it possesses only one Ca^2+-binding site and shows weak membrane association under physiological conditions. Its endogenous expression is restricted to epithelial cells of the gastrointestinal tract. In cancer biology, homozygous deletion or downregulation of ANXA10 has been linked to dedifferentiation, increased invasiveness, and poor patient survival, supporting its proposed role as a tumor suppressor. Overexpression increases cell sensitivity to apoptosis and reduces proliferation. ANXA10 localizes to nuclear paraspeckles, structures involved in mRNA processing and regulation, suggesting a membrane-independent nuclear function. Recent research indicates possible involvement in ferroptosis and autophagy, broadening its potential as a therapeutic target. It is considered a therapeutic target in cancer contexts due to its tumor suppressor function and involvement in disease progression. ANXA10 is a unique annexin with restricted tissue distribution and novel nuclear functions, playing a key role in epithelial cell differentiation and tumor biology.

Other names

Annexin A10ANXA10ANX14Annexin-10Annexin-14

Not established for any approved drug. Proposed therapeutic mechanisms include modulation of apoptosis, autophagy (affecting ferroptosis in colorectal cancer), and tumor suppression.